Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033

Description

The Head and neck squamous cell carcinoma (HNSCC) market is hugely contributed by current standards of care which are Surgical resection, radiotherapy, Chemotherapy, Cetuximab, and Immunotherapy. By 2033, the market is expected to change due to the uptake and launch of new novel therapies. In an HNSCC treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of HNSCC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2019-2033 study period, adding a value estimated at a total market of HNSCC localized/regional therapies $ 3.1 billion whereas HNSCC advanced or metastatic therapies $ 4.4 billion by 2033, totalling USD 7.5 billion market sales.

“Initial therapy may include combinations of surgery, radiation, and platinum-based chemotherapy but the recurrence after platinum-based chemotherapy is associated with a particularly dismal prognosis. Average survival for these patients is less than 6 months. I have been treating patients for 20 years, the disease is devastating, with patients having significant issues with speech, swallowing, and breathing.”

Head and Neck (H&N) Cancer’s addresses tumors originating from the oral cavity (including the mucosal lip), pharynx, larynx, and paranasal sinuses. Squamous cell carcinomas account for more than 95% of these tumors. Tobacco and alcohol use disorders are the most common etiologies for oral cavity, hypopharynx, larynx, and Human Papillomavirus (HPV)-unrelated oropharynx cancers. Patients with H&N cancers due to tobacco and alcohol are at risk for harboring synchronous primary tumors and developing second primary neoplasms in the H&N, lung, esophagus, bladder, and other potential sites exposed to these carcinogens.

Surgical resection of the primary tumor and draining lymph nodes followed by risk-adapted adjuvant radiation, with or without platinum-based chemotherapy, or primary definitive concurrent chemoradiation, remain the principal treatments employed for locally advanced HNSCC. It is important to note that multimodality treatment often drastically impacts patient quality of life (QOL). Treatment planning should aim for the most highly curative approach while optimizing preservation of function.

Recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC) is a challenging disease with limited treatment options. It is often diagnosed when the cancer has spread to other parts of the body or has returned after treatment. The prognosis for RM HNSCC is poor, with a median overall survival of just a few months. However, recent immunotherapy and targeted therapy advances have shown promise in improving outcomes for some patients with RM HNSCC. Clinical trials are ongoing to determine the most effective treatment strategies for this aggressive form of cancer. Early diagnosis and aggressive treatment are critical to improving survival outcomes for patients with RM HNSCC.

Mellalta’s Head and neck squamous cell carcinoma (HNSCC) Report – Market Summary 

Mellalta’s Head and neck squamous cell carcinoma (HNSCC) Report – Epidemiology

The total HNSCC incident cases in the G7 countries are anticipated to increase to 150,447 cases by 2033 for the study period (2019- 2033). As per estimates, the EU5 accounted for the highest incidence of Head and neck squamous cell carcinoma (HNSCC) cases in 2023 which was 63,239 cases and is expected to increase by 2033 for the study period followed by the United States and Japan. Among the EU5, France had the highest AML cases, followed by Germany, the United Kingdom, Spain, and Italy.

Mellalta’s Head and neck squamous cell carcinoma (HNSCC) Report – Current Market Size & Forecast Trends

The current standard of care is limited to surgery, chemotherapy, radiotherapy, and targeted therapies. Early stages Locoregional patients are largely dependent on Surgery, chemotherapy and radiation regimens.  The standard of care for locally advanced unresected squamous cell carcinoma of the head and neck is concurrent chemoradiation with high-dose cisplatin. Treatment with this regimen is associated with less than a 50% disease-free survival and a 5-year overall survival rate of approximately 50%. The current median overall survival for patients with the standard of care is eight months in the recurrent or metastatic settings, highlighting the greatest unmet need for more efficacious treatments that can improve overall survival for HNSCC patients. Hence, we need approaches that improve survival outcomes by adopting curative-intent treatment in an earlier setting, thus reducing the risk of recurrence and making use of targeted therapies in locally advanced settings, which will likely result in prolonged overall survival.

The current standard of care for first-line recurrent metastatic head and neck squamous cell carcinoma is pembrolizumab with or without chemotherapy. Experts favour pembrolizumab and a chemotherapy combination in patients with a higher disease burden and in those who are more symptomatic while reserving pembrolizumab monotherapy for those with lower tumour volume and the highest PDL1 expression. According to KOLs, approximately 20% of patients experiencing recurrent metastatic disease have shown potential for long-term survival when treated with pembrolizumab. However, the current results, while beneficial for some patients, are not considered satisfactory. There is a desire to achieve higher response rates and increase the number of patients who can benefit from this therapy, particularly in terms of long-term survival.

During the forecast period (2019-2033), the market growth is expected to grow which is attributed to the several therapies which are currently launched especially in the R/M segments of the HNSCC market. We expect the drug utilization of the therapies will further increase including Anti-PD-1, and EGFR inhibitors. These established therapies play a pivotal role in addressing Head and neck squamous cell carcinoma, improving patients’ quality of life. Secondly, the introduction of innovative drugs such as ASP-1929 (Rakuten Medical Inc.), Xevinapant (Merck), Atezolizumab (Roche), Buparlisib (Adlai Nortye), Lenvatinib + Pembrolizumab (Merck/Eisai), NBTXR3 (Nanobiotix), Petosemtamab (Merus) adds further momentum to the market expansion, ensuring a comprehensive range of treatment options for patients.

Key Questions Answered  

• What is the size of clinically and commercially relevant drug-treatable Localized and metastatic HNSCC populations, and how will drug-treatment rates of HNSCC change over time?
• Twelve (12) late-stage pipeline agents are going to enter the HNSCC market during the forecast period. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
• What are the current unmet needs in HNSCC, and which pipeline agents are positioned to counter these unmet needs? What are the opportunities for future emerging therapies?
• What is the market outlook in the G7 from 2019-2033? Considering major patent expiries, the launch of new premium-priced agents and expected label expansions.
• Potential challenges and opportunities in implementing targeted therapies for HNSCC.
• What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?
• What key drivers and constraints will affect the HNSCC therapy market over the forecast period?

Report Highlights

• Head and neck squamous cell carcinoma (HNSCC) – Current Market Trends
• Head and neck squamous cell carcinoma (HNSCC) – Current & Forecasted Cases across the G7 Countries
• Head and neck squamous cell carcinoma (HNSCC) – Market Opportunities and Sales Potential for Agents
• Head and neck squamous cell carcinoma (HNSCC) – Patient-based Market Forecast to 2033
• Head and neck squamous cell carcinoma (HNSCC) – Untapped Business Opportunities
• Head and neck squamous cell carcinoma (HNSCC) – Product Positioning Vis-a-vis Competitors’ Products
• Head and neck squamous cell carcinoma (HNSCC) – KOLs Insight